Ellansé vs Gouri
Ellansé and Gouri both use PCL terminology, but they are physically different product systems. Ellansé is documented as PCL microspheres suspended in a carrier gel; Dexlevo describes Gouri as fully solubilized PCL. They should not share an assumed mechanism, spread pattern, immediate effect, or injection protocol.
No direct head-to-head clinical trial was identified for this comparison. It is a structure-and-documentation comparison, not a performance ranking.
Compact comparison
Section titled “Compact comparison”| Field | Ellansé | Gouri |
|---|---|---|
| PCL form | Microspheres | Manufacturer-described solubilized PCL |
| Vehicle or system | Carrier gel containing PBS, glycerin, and CMC | Exact composition must be verified in the current market-specific IFU |
| Presentation | Sterile, single-use, ready-to-use syringe | Verify exact local presentation and instructions |
| Immediate structural effect | Carrier gel provides an immediate correction phase | Do not assume a filler-like carrier effect from the PCL name |
| Company context | Sinclair; legal manufacturer AQTIS Medical B.V. in the current SSCP | Dexlevo manufacturer |
Ellansé fields are supported by its current Summary of Safety and Clinical Performance (Sinclair SSCP 🔗). Dexlevo describes Gouri and its CESABP technology as a fully solubilized PCL system (Dexlevo 🔗).
Particle versus solubilized polymer
Section titled “Particle versus solubilized polymer”For Ellansé, the PCL microspheres and the CMC-containing carrier are separable parts of the product description. The carrier explains an immediate correction phase, while the microsphere-related tissue response is discussed over time.
For Gouri, “solubilized” is a manufacturer description of the polymer system. It should not be translated into claims of uniform diffusion, freedom from nodules, superior safety, or predictable whole-face distribution without compatible clinical evidence.
What must not be transferred
Section titled “What must not be transferred”Do not transfer between the products:
- Ellansé’s carrier behavior
- Gouri’s manufacturer-described solubilized mechanism
- needle, depth, point, or pattern instructions
- approved indications from one country to another
- duration language
- adverse-event rates from unrelated formulations
An Argentinian regulator-hosted document identifies Dexlevo as the Gouri manufacturer (ANMAT document 🔗). Regional documents are useful for role and label verification, but they do not create a global indication.
Evidence and labeling limits
Section titled “Evidence and labeling limits”Ellansé has a public SSCP that supports device description, variants, manufacturer role, and clinical-evidence context. Gouri’s public manufacturer pages explain the technology position, but an exact current local IFU is still required for composition, indication, contraindications, handling, and technique.
Practitioner takeaway
Section titled “Practitioner takeaway”First classify the physical system; then verify the exact label. Read the broader PCL material page and the product-level Ellansé page before drawing clinical conclusions.